News
Videos
Conferences
Events
Resources
Subscribe

News|Videos|April 20, 2016

Top Considerations for Maintenance Therapy

Episodes in this series

EP. 1 Types of Multiple Myeloma

EP. 1 Types of Multiple Myeloma

EP. 2 Testing Procedures and Considerations

EP. 2 Testing Procedures and Considerations

EP. 3 Considerations For Treatment

EP. 3 Considerations For Treatment

EP. 4 Monitoring Patients

EP. 4 Monitoring Patients

EP. 5 Top Considerations for Maintenance Therapy

EP. 5 Top Considerations for Maintenance Therapy

EP. 6 New Drug Classes For Treatment

EP. 6 New Drug Classes For Treatment

EP. 7 Clinical Trials and Stem Cell Transplants

EP. 7 Clinical Trials and Stem Cell Transplants

EP. 8 Professional Expectations for Future

EP. 8 Professional Expectations for Future

Newsletter

Stay up to date on cancer updates, research and education

Related Content

Dr. Suneel Kamath highlighted advances in biomarker-driven therapies and emerging frontline regimens following the 2026 ASCO GI Cancers Symposium.

Key GI Cancer Advances from the 2026 ASCO Symposium

January 30th 2026

breast cancer

Ibrance Adds 15 Months of Progression-Free Survival in HR+, HER2+ Breast Cancer

January 30th 2026

Image of Dr. Obeid.

Risk Assessment Remains Vital for Patients Even After Cancer Diagnosis

ByDr. Elias Obeid

January 30th 2026

Bonnie Annis

The Last Walk Down the Hall: Reflections Before Entering Cancer Survivorship

January 30th 2026

Dr. Brittany Dulmage explains how biotin can interfere with lab testing during cancer care: © The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

Biotin, Lab Interference and Safer Options for Cancer-Related Hair Loss

January 30th 2026

Trending on CURE

Most Patients With HER2+ Breast Cancer Miss Standard Treatment, Study Shows

Study Identifies Why Some Breast Cancers Resist Enhertu Treatment

FDA Accepts Ivonescimab Application for EGFR Lung Cancer

Expert insights into Biomarker-Driven Care and Emerging Targets in GI Cancer

FDA Fast Tracks LBL-034 in Relapsed or Refractory Multiple Myeloma